Simulation of the effect of variable duration of absorption on steady-state plasma levels of drugs administered orally as zero-order delivery systems

Journal of Controlled Release

Volumn 46, Issue 3, 1997, Pages 197-204

  Guédès, Jean Paul ^a   Couet, William ^b  

^a Lycée Descartes   (France)

^b UNIVERSITÉ DE POITIERS   (France)

Author keywords

Absorption; Biopharmaceutics; Pharmacokinetics; Sustained release; Zero order delivery systems

Indexed keywords

ARTICLE; BIOAVAILABILITY; COMPUTER SIMULATION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG RELEASE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STEADY STATE; THEORY;

EID: 0343907313     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(96)01594-5     Document Type: Article

References (14)

1. J. DiPiro, Controlling drug effects through improved oral formulations, Am. J. Med. 87, suppl. 2A, (1989) 31S.
2. G.L. Plosker and S.P. Clissold, Controlled release metoprolol formulations: a review of their pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and ischaemic heart disease, Drugs 43 (1992) 382.
3. I.D. Bradbrook, M. Babiker, P. Crome, H.C. Gillies, P.J. Morrison, H.J. Rogers and P. Shotton, Comparison of pharmacokinetic profiles of single and multiple doses of a slow release Oros oxprenolol delivery system in young normotensive and elderly hypertensive subjects, Br. J. Clin. Pharmacol. 21 (1986) 371.
4. S.S. Davis, N. Washington, G.D. Parr, A.H. Short, V.A. John, P. Lloyd and S.M. Walker, Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol Oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy, Br. J. Clin. Pharmacol. 26 (1988) 435.
5. I.R. Wilding, S.S. Davis, J.G. Hardy, C.S. Robertson, V.A. John, M.L. Powell, M. Leal, P. Lloyd and S.M. Walker, Relationship between systemic drug absorption and gastrointestinal transit after the simultaneous oral administration of carbamazepine as a controlled-release system and as a suspension of 15N-labelled drug to healthy volunteers, Br. J. Clin. Pharmacol. 32 (1991) 573.
6. P.A. Soons, A.G. de Boer, P. van Brummelen and D.D. Breimer, Oral absorption profile of nitrendipine in healthy subjects: a kinetic and dynamic study, Br. J. Clin. Pharmacol. 27 (1989) 179.
7. P.A. Meredith, H.L. Elliott, J. Vincent and J.L. Reid, A clinical pharmacological assessment of a new osmotic pump formulation of prazosin, Br. J. Clin. Pharmacol. 22 (1986) 235P.
8. R. Schall, F.O. Muller, H.K.L. Hundt, L. Duursema, G. Groenewoud, M. Van Dyk and A.M.C. Van Schalkwyk, Relative bioavailability of four controlled-release nifedipine products, Biopharm. Drug Dispos. 15 (1994) 493.
9. S.T. Chao, D. Prather, D. Pinson, P. Coen, B. Pruitt, M. Knowles and V. Place, Effect of food on bioavailability of pseudoephedrine and brompheniramine administered from a gastrointestinal therapeutic system, J. Pharm. Sci. 80 (1991) 432.
10. J. Hirtz, Problems of bioavailability with new drug delivery systems, Pharm. Int. 7 (1986) 21.
11. H. Boxenbaum, Pharmacokinetic determinants in the design and evaluation of sustained-release dosage forms, Pharm. Res. (1984) 82.
12. W.K. Cheung, A. Yacobi and B.M. Silber, Pharmacokinetic approach to the rational design of controlled or sustained release formulations, J. Control. Rel. 5 (1988) 263.
13. W.K. Cheung, B.M. Silber and A. Yacobi, Pharmacokinetic principles in the design of immediate-release components in sustained-release formulations with zero-order release characteristics, J. Pharm. Sci. 80 (1991) 142.
14. G. van den Berg, F. van Steveninck, J.M. Gubbens-Stibbe, H.C. Schoemaker, A.G. de Boer and A.F. Cohen, Influence of food on the bioavailability of metoprolol from an OROS system; a study in healthy volunteers, Eur. J. Clin. Pharmacol. 39 (1990) 315.